4.9/5 - (280 votes)

Polyfocal trephine biopsy (7–12 locations) — is an extended histological examination of prostate tissue obtained by taking columns of tissue from different anatomical areas of the gland. Taking material from 7–12 points is considered the current standard («systematic biopsy»), as it provides high accuracy in detecting cancer, covering the peripheral and central areas of both lobes of the organ.

Research objective: The main task is to maximize the coverage of gland tissues to detect foci of adenocarcinoma, which are often small and arranged in a mosaic pattern. Such a scope of study under the code PG055 minimizes the risk of obtaining a false-negative result and allows the pathologist to provide the most complete characterization of the tumor aggressiveness.

What does the pathologist evaluate:

Presence and type of malignancy: confirmation of the diagnosis of adenocarcinoma and determination of its histological variant.
Gleason Score: Calculating a score for each positive site is critical for understanding the tumor's potential for metastasis.
Multifocality: analysis of the distribution of the tumor throughout the gland (whether one lobe or both are affected).
Extent of lesion: measurement of the length of tumor tissue in each column (in millimeters or percentage).
Condition of the capsule and nerves: detection of signs of tumor growth beyond the gland or along nerve endings (perineural invasion).
Associated pathologies: diagnosis of background prostatitis, atrophy or signs of benign hyperplasia.

Clinical significance: The results of the study of 12 localizations give the urologist-oncologist a complete "map" of the disease. This allows you to accurately determine the risk group according to the D'Amico classification and choose between radical surgery, radiation therapy or active surveillance tactics. A large number of samples allows you to more accurately predict the course of the disease and the likelihood of recurrence.

When is it prescribed:

primary diagnosis for suspected prostate cancer (PSA > 4 ng/ml or suspicious digital rectal examination results);
the need to clarify the stage before performing radical surgery;
follow-up examination of patients who previously had questionable biopsy results (e.g., ASAP or high-grade PIN);
an "active surveillance" program for patients with already diagnosed low-grade cancer.
Polyfocal trephine biopsy (7–12 locations) — is an extended histological examination of prostate tissue obtained by taking columns of tissue from different anatomical areas of the gland. Taking material from 7–12 points is considered the current standard («systematic biopsy»), as it provides high accuracy in detecting cancer, covering the peripheral and central areas of both lobes of the organ.
Research objective: The main task is to maximize the coverage of gland tissues to detect foci of adenocarcinoma, which are often small and arranged in a mosaic pattern. Such a scope of study under the code PG055 minimizes the risk of obtaining a false-negative result and allows the pathologist to provide the most complete characterization of the tumor aggressiveness.
What does the pathologist evaluate:
- Presence and type of malignancy: confirmation of the diagnosis of adenocarcinoma and determination of its histological variant.
- Gleason Score: Calculating a score for each positive site is critical for understanding the tumor's potential for metastasis.
- Multifocality: analysis of the distribution of the tumor throughout the gland (whether one lobe or both are affected).
- Extent of lesion: measurement of the length of tumor tissue in each column (in millimeters or percentage).
- Condition of the capsule and nerves: detection of signs of tumor growth beyond the gland or along nerve endings (perineural invasion).
- Associated pathologies: diagnosis of background prostatitis, atrophy or signs of benign hyperplasia.
Clinical significance: The results of the study of 12 localizations give the urologist-oncologist a complete "map" of the disease. This allows you to accurately determine the risk group according to the D'Amico classification and choose between radical surgery, radiation therapy or active surveillance tactics. A large number of samples allows you to more accurately predict the course of the disease and the likelihood of recurrence.
When is it prescribed:
- primary diagnosis for suspected prostate cancer (PSA > 4 ng/ml or suspicious digital rectal examination results);
- the need to clarify the stage before performing radical surgery;
- follow-up examination of patients who previously had questionable biopsy results (e.g., ASAP or high-grade PIN);
- an "active surveillance" program for patients with already diagnosed low-grade cancer.